Literature DB >> 2963191

Human blood-brain barrier insulin-like growth factor receptor.

K R Duffy1, W M Pardridge, R G Rosenfeld.   

Abstract

Insulin-like growth factor (IGF)-1 and IGF-2, may be important regulatory molecules in the CNS. Possible origins of IGFs in brain include either de novo synthesis or transport of circulating IGFs from blood into brain via receptor mediated transcytosis mechanisms at the brain capillary endothelial wall, ie, the blood-brain barrier (BBB). In the present studies, isolated human brain capillaries are used as an in vitro model system of the human BBB and the characteristics of IGF-1 or IGF-2 binding to this preparation were assessed. The total binding of IGF-2 at 37 degrees C exceeded 130% per mg protein and was threefold greater than the total binding for IGF-1. However, at 37 degrees C nonsaturable binding equaled total binding, suggesting that endocytosis is rate limiting at physiologic temperatures. Binding studies performed at 4 degrees C slowed endocytosis to a greater extent than membrane binding, and specific binding of either IGF-1 or IGF-2 was detectable. Scatchard plots for either peptide were linear and the molar dissociation constant of IGF-1 and IGF-2 binding was 2.1 +/- 0.4 and 1.1 +/- 0.1 nmol/L, respectively. Superphysiologic concentrations of porcine insulin inhibited the binding of both IGF-1 (ED50 = 2 micrograms/mL) and IGF-2 (ED50 = 0.5 microgram/mL). Affinity cross linking of 125I-IGF-1, 125I-IGF-2, and 125I-insulin to isolated human brain capillaries was performed using disuccinimidylsuberate (DSS). These studies revealed a 141 kd binding site for both IGF-1 and IGF-2, and a 133 kd binding site for insulin.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2963191     DOI: 10.1016/s0026-0495(98)90007-5

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  34 in total

Review 1.  Molecular biology of the insulin-like growth factors. Relevance to nervous system function.

Authors:  J E Hepler; P K Lund
Journal:  Mol Neurobiol       Date:  1990 Spring-Summer       Impact factor: 5.590

2.  Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders.

Authors:  Silvia Muro
Journal:  Drug Deliv Transl Res       Date:  2012-06-01       Impact factor: 4.617

Review 3.  Strategies to improve drug delivery across the blood-brain barrier.

Authors:  Albertus G de Boer; Pieter J Gaillard
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 4.  Blood-brain barrier and new approaches to brain drug delivery.

Authors:  W M Pardridge; R J Boado; K L Black; P A Cancilla
Journal:  West J Med       Date:  1992-03

Review 5.  Drug transport across the blood-brain barrier.

Authors:  William M Pardridge
Journal:  J Cereb Blood Flow Metab       Date:  2012-08-29       Impact factor: 6.200

6.  Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor.

Authors:  M J Coloma; H J Lee; A Kurihara; E M Landaw; R J Boado; S L Morrison; W M Pardridge
Journal:  Pharm Res       Date:  2000-03       Impact factor: 4.200

Review 7.  Transendothelial Transport and Its Role in Therapeutics.

Authors:  Ravi Kant Upadhyay
Journal:  Int Sch Res Notices       Date:  2014-08-27

8.  Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.

Authors:  Brian Spencer; Ivy Trinh; Edward Rockenstein; Michael Mante; Jazmin Florio; Anthony Adame; Omar M A El-Agnaf; Changyoun Kim; Eliezer Masliah; Robert A Rissman
Journal:  Neurobiol Dis       Date:  2019-03-05       Impact factor: 5.996

Review 9.  Insulin and insulin-like growth factor receptors in the nervous system.

Authors:  M Adamo; M K Raizada; D LeRoith
Journal:  Mol Neurobiol       Date:  1989 Spring-Summer       Impact factor: 5.590

10.  Transferrin-antibody fusion proteins are effective in brain targeting.

Authors:  S U Shin; P Friden; M Moran; T Olson; Y S Kang; W M Pardridge; S L Morrison
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.